600511 国药股份
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入52,468,2813.70%49,696,04645,498,58446,468,60340,378,608
减:营业总成本50,383,1294.09%47,194,08943,218,51344,351,26738,790,277
    其中:营业成本49,008,4434.27%45,704,77641,676,31842,837,50037,235,801
               财务费用(21,877)-67.84%(126,127)(28,840)(18,342)(6,810)
               资产减值损失(5,564)421.78%389(5,140)(17,588)(6,479)
公允价值变动收益66-100.36%10,817------
投资收益566,77710.23%358,952291,622283,351220,599
    其中:对联营企业和合营企业的投资收益546,9946.18%456,539380,800380,222327,623
营业利润2,621,664-2.08%2,944,3582,694,9232,447,2741,913,218
利润总额2,600,143-2.01%2,930,8902,687,8862,444,8061,917,346
减:所得税费用510,739-2.50%596,420559,181516,303408,095
净利润2,089,404-1.90%2,334,4712,128,7051,928,5031,509,251
减:非控股权益92,810-28.42%188,472164,648174,418126,562
股东净利润1,996,593-0.18%2,145,9991,964,0581,754,0841,382,688

市场价值指针
每股收益 (元) *2.646-0.18%2.8442.6032.3251.833
每股派息 (元) *0.8000.00%0.8540.7820.7000.550
每股净资产 (元) *24.5798.27%20.90918.84016.93815.167
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容